Xylometazoline: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page

Xylometazoline

Active ingredient · 3 therapeutic classes

GB MHRA

Drug class: Sympathomimetics, Plain
Availability: See label
Markets covered: 1
Products on record: 11

R01AASympathomimetics, Plain R01ABSympathomimetics, Combinations Excl. Corticosteroids S01GASympathomimetics Used As Decongestants

Overview

Xylometazoline is an active pharmaceutical ingredient in the Sympathomimetics, Plain group (R01AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	11	May 22, 2026

GBUnited Kingdom· MHRA

11 products

Uses

GBOfficial regulatory label· revised September 19, 2025[1]

For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitis.

How to take

Drug interactions

Known interactions involving Xylometazoline. Select one for details. This list is informational and not a complete interaction checker.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL446730184 · revised September 19, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised September 19, 2025[1]

The adverse effects listed below are classified by system organ class and frequency according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) or very rare (<1/10,000).
MeDRA SOC Adverse reaction Frequency Immune System Disorders Hypersensitivity reaction (angioedema, rash, pruritus) Very rare Nervous System Disorders Headache Common Eye Disorders Transient visual impairment Very rare Cardiac Disorders Heart rate irregular Heart rate increased Very rare Very rare Respiratory, thoracic and mediastinal disorders Nasal Dryness Nasal Discomfort Epistaxis Common Common Uncommon Gastrointestinal disorders Nausea Common General disorders and administration site Application site burning Common Other side effects include: • A burning sensation in the nose and throat Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.

GBOfficial regulatory label· Warnings and precautions· revised September 19, 2025[1]

Patients are advised not to take decongestants for more than seven consecutive days, prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa. Otrivine, like other preparations belonging to the same class of active substances, should be used only with caution in patients showing a strong reaction to sympathomimetic agents as evidenced by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure.
Caution is recommended in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus or tri and tetra-cyclic antidepressant treatment (see Interactions). Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias.
Keep medicines out of the sight and reach of children. Information concerning excipients Otrivine contains benzalkonium chloride. This may cause irritation of the nasal mucosa.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations